What is the recommended treatment for invasive Aspergillus infection, especially with possible central nervous system involvement?

Treatment of Invasive Aspergillus Infection

Voriconazole is the first-line treatment for invasive aspergillosis, including CNS involvement, with a loading dose of 6 mg/kg IV every 12 hours for 2 doses, followed by 4 mg/kg IV every 12 hours (or 200-300 mg orally every 12 hours once stable). 1, 2

Primary Treatment Approach

First-Line Therapy

• Voriconazole is the gold standard based on superior survival data (71% vs 58% at 12 weeks) and improved response rates (53% vs 32%) compared to amphotericin B deoxycholate 3
• For CNS aspergillosis specifically, voriconazole is strongly preferred because it achieves fungicidal concentrations in cerebrospinal fluid and brain tissue—unlike amphotericin B or itraconazole which penetrate poorly 4, 5, 6
• Higher dosages may be needed for Aspergillus flavus and Aspergillus terreus compared to Aspergillus fumigatus 1
• Therapeutic drug monitoring is essential to optimize dosing 1

Alternative Agents (if voriconazole contraindicated or not tolerated)

• Liposomal amphotericin B (L-AmB) 3-5 mg/kg IV daily 1, 2
• Isavuconazole 200 mg every 8 hours for 6 doses, then 200 mg daily 2
• Amphotericin B deoxycholate should only be used if no alternatives are available due to severe nephrotoxicity 1

CNS-Specific Considerations

When CNS involvement is present or suspected:

• Surgical resection of infected tissue should be pursued if feasible—this is critical for improving outcomes 1, 2
• Be vigilant about drug interactions between voriconazole and anticonvulsants (phenytoin, carbamazepine, phenobarbital can reduce voriconazole levels) 1
• Combination therapy may be considered in selected patients with proven/probable CNS aspergillosis, though not routinely recommended for primary therapy 1
• Some case reports suggest intrathecal amphotericin B as adjunctive therapy in refractory CNS cases, though this remains investigational 7
• CNS aspergillosis carries the highest mortality among all invasive aspergillosis patterns—approaching 90-100% historically, though voriconazole has improved this to approximately 31% survival 3, 5

Salvage Therapy Options

If primary therapy fails or is not tolerated:

• Echinocandins (caspofungin 70 mg loading, then 50 mg daily; micafungin 100-150 mg daily) are effective in salvage but NOT as primary monotherapy 1
• Posaconazole (oral suspension 200 mg QID initially, then 400 mg BID; or tablet/IV formulations at 300 mg BID day 1, then 300 mg daily) 1, 2
• Itraconazole (200 mg twice daily orally) 1
• Consider switching to a different antifungal class or combination therapy 1

Treatment Duration and Monitoring

• Minimum 6-12 weeks of therapy, but duration varies based on:
  • Site and extent of disease
  • Degree and duration of immunosuppression
  • Evidence of clinical and radiological improvement 1
• Continue therapy throughout the period of immunosuppression and until lesions resolve 3
• Serial CT imaging should be performed at individualized intervals based on disease acuity 3
• Pulmonary infiltrates may paradoxically increase in the first 7-10 days, especially with neutrophil recovery 3

Critical Management Steps for Treatment Failure

When facing breakthrough infections or treatment failures:

1. Review the diagnosis and confirm invasive aspergillosis
2. Test antifungal susceptibility (especially important given emerging azole resistance) 1
3. Review drug interactions that may reduce antifungal levels 1
4. Perform therapeutic drug monitoring for azoles 1
5. Reduce immunosuppression if clinically feasible 1
6. Pursue surgical resection of necrotic tissue 1
7. Investigate alternative etiologies 1
8. Switch antifungal class or add combination therapy 1

Important Caveats

• Primary combination therapy is NOT routinely recommended based on lack of clinical trial data supporting improved outcomes 1, 3, 2
• For patients requiring subsequent immunosuppression after successful treatment, secondary prophylaxis should be initiated to prevent recurrence 1
• Voriconazole causes transient visual disturbances in many patients—counsel them that this is expected and usually resolves 3
• Pediatric dosing differs: voriconazole 5-7 mg/kg IV every 12 hours (not 4 mg/kg as in adults) 3